Clinical Trial Update: ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

ARCHER 1009 is a Phase 3 trial comparing dacomitinib (PF-00299804) with erlotinib in advanced non-small cell lung cancer. The results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• VIZIMPRO (dacomitinib)

Snippet

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2017-05-24